Floatz logo

Eloxatin

MSS/pMMR

Qilu Hospital of Shandong UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the MSS/pMMR cohort.

Asset / SponsorPhaseRating
Iparomlimab
Qilu Hospital of Shandong University
Phase 2CCC
Tislelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC
Capecitabine
Qilu Hospital of Shandong University
Phase 2CCC

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →